


Variant Analysis

Bioinformatics for Systems and Synthetic Biology

Emidio Capriotti
<http://biofold.org/emidio>



**Biomolecules
Folding and
Disease**

Department of Pharmacy and
Biotechnology (FaBiT)
University of Bologna



Single Nucleotide Variants

Single Nucleotide Variants (SNVs)

is a DNA sequence variation occurring when a single nucleotide A, T, C, or G in the genome differs between members of the species.


It is used to refer to Polymorphisms when the population frequency is $\geq 1\%$

SNVs occur at any position and **can be classified on the base of their locations.**

Coding SNVs can be subdivided into two groups:

Synonymous: when single base substitutions do not cause a change in the resultant amino acid

Non-synonymous or Single Amino Acid Variants (SAVs): when single base substitutions cause a change in the resultant amino acid.



Effects of variants

It is important to understand the **functional effect of Single Nucleotide Polymorphisms** (SNPs) that are very common type of variations, but also the impact **rare variants** which have allele frequencies below than 1%

Impact of **coding variants**

- Properties of amino acid residue substitution
- The evolutionary history of an amino acid position
- Sequence–function relationships
- Structure–function relationships

Impact of **non-coding variants**

- Transcription
- Pre-mRNA splicing
- MicroRNA binding
- Altering post-translational modification sites

1000 Genomes

The 1000 Genomes Project aims to create the **largest public catalogue of human variations and genotype data**. Last version released the genotype of ~2,500 individuals.


Table 1 | Variants discovered by project, type, population and novelty

a Summary of project data including combined exon populations

Statistic	Low coverage				Trios			Exon (total)	Union across projects
	CEU	YRI	CHB+JPT	Total	CEU	YRI	Total		
Samples	60	59	60	179	3	3	6	697	742
Total raw bases (Gb)	1,402	874	596	2,872	560	615	1,175	845	4,892
Total mapped bases (Gb)	817	596	468	1,881	369	342	711	56	2,648
Mean mapped depth (×)	4.62	3.42	2.65	3.56	43.14	40.05	41.60	55.92	NA
Bases accessed (% of genome)	2.43 Gb (86%)	2.39 Gb (85%)	2.41 Gb (85%)	2.42 Gb (86.0%)	2.26 Gb (79%)	2.21 Gb (78%)	2.24 Gb (79%)	1.4 Mb	NA
No. of SNPs (% novel)	7,943,827 (33%)	10,938,130 (47%)	6,273,441 (28%)	14,894,361 (54%)	3,646,764 (11%)	4,502,439 (23%)	5,907,699 (24%)	12,758 (70%)	15,275,256 (55%)
Mean variant SNP sites per individual	2,918,623	3,335,795	2,810,573	3,019,909	2,741,276	3,261,036	3,001,156	763	NA
No. of indels (% novel)	728,075 (39%)	941,567 (52%)	666,639 (39%)	1,330,158 (57%)	411,611 (25%)	502,462 (37%)	682,148 (38%)	96 (74%)	1,480,877 (57%)
Mean variant indel sites per individual	354,767	383,200	347,400	361,669	322,078	382,869	352,474	3	NA
No. of deletions (% novel)	ND	ND	ND	15,893 (60%)	6,593 (41%)	8,129 (50%)	11,248 (51%)	ND	22,025 (61%)
No. of genotyped deletions (% novel)	ND	ND	ND	10,742 (57%)	ND	ND	6,317 (48%)	ND	13,826 (58%)
No. of duplications (% novel)	259 (90%)	320 (90%)	280 (91%)	407 (89%)	187 (93%)	192 (91%)	256 (92%)	ND	501 (89%)
No. of mobile element insertions (% novel)	3,202 (79%)	3,105 (84%)	1,952 (76%)	4,775 (86%)	1,397 (68%)	1,846 (78%)	2,531 (78%)	ND	5,370 (87%)
No. of novel sequence insertions (% novel)	ND	ND	ND	ND	111 (96%)	66 (86%)	174 (93%)	ND	174 (93%)

SNVs and SAVs databases

dbSNP @ NCBI



<http://www.ncbi.nlm.nih.gov/snp>

Single Nucleotide Variants

Homo sapiens **904,623,795**

SwissVar @ ExPASy



<http://www.expasy.ch/swissvar/>

Single Amino acid Variants

Homo sapiens **83,996**

Disease **32,930**

Polymorphisms **39,938**

Variant Call Format

The final result of the variant calling procedure is a VCF file.

```
##fileformat=VCFv4.1
##tcgaversion=1.1
##reference=<ID=hg19,source=>
##phasing=none
##geneAnno=none
##INFO=<ID=VT,Number=1,Type=String,Description="Variant type, can be SNP, INS or DEL">
##INFO=<ID=VLS,Number=1,Type=Integer,Description="Final validation status relative to non-adjacent Normal, .....">
##FILTER=<ID=CA,Description="Fail Carnac (Tumor and normal coverage, tumor variant count, mapping quality, .....">
##FORMAT=<ID=GT,Number=1,Type=String,Description="Genotype">
##FORMAT=<ID=DP,Number=1,Type=Integer,Description="Read depth at this position in the sample">
##FORMAT=<ID=AD,Number=.,Type=Integer,Description="Depth of reads supporting alleles 0/1/2/3...">
##FORMAT=<ID=BQ,Number=.,Type=Integer,Description="Average base quality for reads supporting alleles">
##FORMAT=<ID=SS,Number=1,Type=Integer,Description="Variant status relative to non-adjacent Normal,0=wildtype, .....">
##FORMAT=<ID=SSC,Number=1,Type=Integer,Description="Somatic score between 0 and 255">
##FORMAT=<ID=MQ60,Number=1,Type=Integer,Description="Number of reads (mapping quality=60) supporting variant">
#CHROM POS ID REF ALT QUAL FILTER INFO FORMAT NORMAL PRIMARY
1 10048 . C CCT . CA VT=INS;VLS=5 GT:DP:AD:BQ:SS:SSC:MQ60 0/0:66:.,0:::0:::0 0/1:32:.,2:::2:::0
1 10078 . CT C . CA VT=DEL;VLS=5 GT:DP:AD:BQ:SS:SSC:MQ60 0/0:25:.,0:::0:::0 0/1:13:.,2:::2:::0
1 10177 . A AC . CA VT=INS;VLS=5 GT:DP:AD:BQ:SS:SSC:MQ60 0/0:57:.,0:::0:::0 0/1:22:.,2:::2:::0
. . .
. . .
1 900505 . G C . PASS VT=SNP;VLS=5 GT:DP:AD:BQ:SS:SSC:MQ60 0/1:188:.,89:26:1:::81 0/1:210:.,113:24:1:::100
. . .
. . .
1 1991007 . G T . PASS VT=SNP;VLS=5 GT:DP:AD:BQ:SS:SSC:MQ60 0/0:222:.,1:2:0:::1 0/1:88:.,41:25:2:50:34
. . .
```

File Content

The file contains information about **single nucleotide variants and indels** of single or multiple samples.

For each variant the number of **supporting reads** for reference and alternative allele

The original VCF does not contain any information **functional effect** of the variants.

Main data sources

Single genetic variants are collected in different databases:


- **dbSNP** - variation from all species. <http://www.ncbi.nlm.nih.gov/SNP/>
- **EVS** - specific for human. <http://evs.gs.washington.edu/EVS/>
- **ClinVar** - Variants and human health. <http://www.ncbi.nlm.nih.gov/clinvar/>
- **Cosmic** - Somatic mutation in cancer. <http://cancer.sanger.ac.uk/>

This information is important for variant calling but **useless for capturing the complexity of genotype/phenotype** relationship. The VCF more informative because we can analyze co-occurring events. The major sources are:

- **1000 Genomes**: WGS data of individuals <http://www.1000genomes.org/>
- **TCGA**: Cancer Genomes <https://tcga-data.nci.nih.gov/>

All in One

Exomizer is a variant analysis tools that tests presence of variants associated to specific phenotypes



The screenshot shows the Wellcome Trust Sanger Institute website with a search bar and navigation menu. The main content area is titled "Exomiser Analysis Options" and contains two sections: "Upload Sample Files" and "Enter Sample Phenotypes".

Upload Sample Files

VCF file: No file chosen

Required. Upload exome sequencing results in VCF format. We can only accept files containing up to 100000 variants. [Example file](#) with causative FGFR2 variant for the autosomal dominant Pfeiffer syndrome added to exome of a healthy individual 

PED file: No file chosen

Only required for multi-sample VCF files

Enter Sample Phenotypes

Phenotypes associated with Mendelian disease:

Clinical phenotypes:

Input terms from the [HPO](#). These will override any phenotypes derived from the specified disease!

<http://www.sanger.ac.uk/resources/software/exomiser/submit/>

The complexity of cancer


Cancer is **complex disorder** characterized by high level of mutation rate.

Mutations can be classified in **germline and somatic** whether they are inherited from parents or the result of error in DNA replication.

Another classification is between **driver and passenger** mutations whether they provide selective advantage with respect to normal cells increasing their proliferation rate or not.


Hallmarks of cancer

The six hallmarks of cancer - distinctive and complementary capabilities that enable tumor growth and metastatic dissemination.



Oncogene vs Suppressor


Oncogenes have highly recurrent mutations, Tumor suppressors have sparse variants.



Main challenges

Computational methods for cancer genome interpretation have been developed to address the following issues:

- Detection of **recurrent somatic mutations** and **cancer driver genes**;
- Prediction of **driver variants** and their functional impact;
- Estimate the **impact of multiple variants** at network and pathway level;
- Differentiate **subclonal populations** and their variation pattern.



How data looks like?

Variant Calling File (VCF) with germline and somatic variants

```
##fileformat=VCFv4.1
##tcgaversion=1.1
##reference=<ID=hg19,source=.>
##phasing=none
##geneAnno=none
##INFO=<ID=VT,Number=1,Type=String,Description="Variant type, can be SNP, INS or DEL">
##INFO=<ID=VLS,Number=1,Type=Integer,Description="Final validation status relative to non-adjacent Normal, .....">
##FILTER=<ID=CA,Description="Fail Carnac (Tumor and normal coverage, tumor variant count, mapping quality, .....">
##FORMAT=<ID=GT,Number=1,Type=String,Description="Genotype">
##FORMAT=<ID=DP,Number=1,Type=Integer,Description="Read depth at this position in the sample">
##FORMAT=<ID=AD,Number=.,Type=Integer,Description="Depth of reads supporting alleles 0/1/2/3...">
##FORMAT=<ID=BQ,Number=.,Type=Integer,Description="Average base quality for reads supporting alleles">
##FORMAT=<ID=SS,Number=1,Type=Integer,Description="Variant status relative to non-adjacent Normal,0=wildtype, .....">
##FORMAT=<ID=SSC,Number=1,Type=Integer,Description="Somatic score between 0 and 255">
##FORMAT=<ID=MQ60,Number=1,Type=Integer,Description="Number of reads (mapping quality=60) supporting variant">
#CHROM POS ID REF ALT QUAL FILTER INFO FORMAT NORMAL PRIMARY
1 10048 . C CCT . CA VT=INS;VLS=5 GT:DP:AD:BQ:SS:SSC:MQ60 0/0:66:.,0:::0:::0 0/1:32:.,2:::2:::0
1 10078 . CT C . CA VT=DEL;VLS=5 GT:DP:AD:BQ:SS:SSC:MQ60 0/0:25:.,0:::0:::0 0/1:13:.,2:::2:::0
1 10177 . A AC . CA VT=INS;VLS=5 GT:DP:AD:BQ:SS:SSC:MQ60 0/0:57:.,0:::0:::0 0/1:22:.,2:::2:::0
. . .
. . .
1 900505 . G C . PASS VT=SNP;VLS=5 GT:DP:AD:BQ:SS:SSC:MQ60 0/1:188:.,89:26:1:::81 0/1:210:.,113:24:1:::100
. . .
1 1991007 . G T . PASS VT=SNP;VLS=5 GT:DP:AD:BQ:SS:SSC:MQ60 0/0:222:.,1:2:0:::1 0/1:88:.,41:25:2:50:34
. . .
```

The TCGA data

The Cancer Genome Atlas Consortium

TCGA data (<https://portal.gdc.cancer.gov/>)

- 91 cancer projects (~50,270 cases)
- BAM files available




The ICGC AR%GO

The International Cancer Genome Consortium




ICGC (<https://platform.icgc-argo.org/>)

- 5,528 Donors
- 429.22 TB data
- 77.4 million simple somatic mutations.



Somatic Mutations

Number of somatic mutations per sample vary significantly across cancer types






Driver vs Passenger

Number of recurrent mutations decrease exponentially.


On average a small fraction of variants are present in the majority of the samples.

Selecting mutations that are repeated at least twice we filter out ~98% mutations and are still able to recover ~96% of the patients



The Cancer Tree

The analysis of **recurrent somatic mutations** can be used to define similarities across cancer types.




Recurrent variations

Recurrent mutations that are found in more samples than would be expected by chance are **good candidates for driver mutations**.

To identify such recurrent mutations, a statistical test is performed which usually **collapses all the non-synonymous mutations in a gene**.

Identification of recurrent mutations in **predefined groups** such as pathways and protein-protein interaction networks and de novo identification of **combinations**, without relying on a priori definition.



The main idea

Genes implicated in cancer should have **high mutation rate**

In comparison to normal, **tumor cells** should have **higher occurrence of functional mutations** in genes involved in the insurgence and progression of the disease.



Problem:

How can we select mutations with functional impact?

Average number of variants	~3,000,000
Average exome variants	~23,000
Average nonsynonymous single nucleotide variants	~10,000
Average rare (MAF≤0.5%) nonsynonymous single nucleotide variants	~300


Variants and MAF

Rare variants are more likely to be associated to disease than high frequency variants



Rate Variants and Genes

On average tumor samples (COAD) have ~150 more rare missense variants and mutated genes



Mutation rates

The analysis of **1000 Genomes, The Cancer Genome Atlas (TCGA)** normal and tumor samples shows an **increasing number of genes with rare nonsynonymous SNVs**.

Cohort	%Genes PDR≤0.05	%Genes PDR>0.05
1000 Genomes	95%	5%
TCGA Normal	92%	8%
TCGA Tumor	82%	18%

Tumor = Colon Adenocarcinoma

PDR = Gene Putative Defective Rate

Fraction of samples in which a gene has ≥ 1 nonsynonymous variant with MAF $\leq 0.5\%$

